- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03521154
A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA) (LAURA)
April 25, 2024 updated by: AstraZeneca
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, International Study of Osimertinib as Maintenance Therapy in Patients With Locally Advanced, Unresectable EGFR Mutation-positive Non-Small Cell Lung Cancer (Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy (LAURA).
A global study to assess the efficacy and safety of osimertinib following chemoradiation in patients with stage III unresectable Epidermal Growth Factor Receptor Mutation Positive non-small cell lung cancer
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
This is a phase 3 double-blind, randomized, placebo-controlled, study to assess the efficacy and safety of osimertinib following chemoradiation in patients with stage III unresectable EGFR mutation-positive NSCLC, including the most common EGFR sensitising mutations (Ex19Del and L858R), either alone or in combination with other EGFR mutations.
Chemoradiation may have been given either given concurrently or sequentially.
Patients whose disease has not progressed following chemoradiation will be randomised within 6 weeks of completion of chemoradiation to receive osimertinib or placebo in a 2:1 ratio, and treatment will be continued until disease progression, unacceptable toxicity or other discontinuation criteria are met.
After progression, patients can be unblinded and may receive open-label osimertinib.
After the final OS analysis, the study blind will be broken and patients still receiving open-label osimertinib will be supplied with open-label osimertinib by AstraZeneca for as long as their treating physician considers they are deriving clinical benefit.
Study Type
Interventional
Enrollment (Actual)
216
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Ciudad Autónoma de Bs. As., Argentina, C1199ABB
- Research Site
-
Ciudad Autónoma de Bs. As., Argentina, 1426
- Research Site
-
Mar del Plata, Argentina, 7600
- Research Site
-
Rosario, Argentina, 2000
- Research Site
-
San Salvador de Jujuy, Argentina, 4600
- Research Site
-
-
-
-
-
Barretos, Brazil, 14784-400
- Research Site
-
Curitiba, Brazil, 81520-060
- Research Site
-
Florianópolis, Brazil, 88034-000
- Research Site
-
Fortaleza, Brazil, 60336-045
- Research Site
-
Porto Alegre, Brazil, 90610-000
- Research Site
-
Porto Alegre, Brazil, 90160-093
- Research Site
-
Ribeirão Preto, Brazil, 14021-636
- Research Site
-
Sao Paulo, Brazil, 01221-0100
- Research Site
-
São Paulo, Brazil, 01246-000
- Research Site
-
-
-
-
-
Beijing, China, 100021
- Research Site
-
Beijing, China, 100730
- Research Site
-
Changchun, China, 130000
- Research Site
-
Changsha, China, 410013
- Research Site
-
Chengdu, China, 610041
- Research Site
-
Guangzhou, China, 510100
- Research Site
-
Hangzhou, China, 310006
- Research Site
-
Hangzhou, China, 310022
- Research Site
-
Hangzhou, China, 310003
- Research Site
-
Jinan, China, 250117
- Research Site
-
Linhai, China, 317000
- Research Site
-
Shanghai, China, 200032
- Research Site
-
Shanghai, China, 200030
- Research Site
-
Urumqi, China, 830099
- Research Site
-
Wuhan, China, 430022
- Research Site
-
Wuhan, China, 430030
- Research Site
-
-
-
-
-
Budapest, Hungary, 1083
- Research Site
-
Budapest, Hungary, 1121
- Research Site
-
Gyöngyös - Mátraháza, Hungary, 3200
- Research Site
-
Pécs, Hungary, 7623
- Research Site
-
-
-
-
-
Bangalore, India, 560068
- Research Site
-
Gurgaon, India, 122001
- Research Site
-
Hubli, India, 580025
- Research Site
-
Karamsad, India, 388325
- Research Site
-
Kolkata, India, 700160
- Research Site
-
Nashik, India, 422002
- Research Site
-
New Delhi, India, 110063
- Research Site
-
New Delhi, India, 110085
- Research Site
-
New Delhi, India, 11029
- Research Site
-
-
-
-
-
Hiroshima-shi, Japan, 734-8551
- Research Site
-
Kanazawa-shi, Japan, 920-8641
- Research Site
-
Kashiwa, Japan, 227-8577
- Research Site
-
Nagoya-shi, Japan, 460-0001
- Research Site
-
Niigata-shi, Japan, 951-8566
- Research Site
-
Osaka-shi, Japan, 541-8567
- Research Site
-
Osakasayama, Japan, 589-8511
- Research Site
-
Sakai-shi, Japan, 591-8555
- Research Site
-
Sapporo-shi, Japan, 003-0804
- Research Site
-
Sendai-shi, Japan, 980-0873
- Research Site
-
Shinjuku-ku, Japan, 160-0023
- Research Site
-
Sunto-gun, Japan, 411-8777
- Research Site
-
Yokohama-shi, Japan, 241-8515
- Research Site
-
-
-
-
-
Cheongju-si, Korea, Republic of, 28644
- Research Site
-
Incheon, Korea, Republic of, 21565
- Research Site
-
Seongnam-si, Korea, Republic of, 13620
- Research Site
-
Seoul, Korea, Republic of, 05505
- Research Site
-
Seoul, Korea, Republic of, 06351
- Research Site
-
-
-
-
-
George Town, Malaysia, 10450
- Research Site
-
Kuala Lumpur, Malaysia, 59100
- Research Site
-
Selangor, Malaysia, 46050
- Research Site
-
-
-
-
-
Mérida, Mexico, 97134
- Research Site
-
-
-
-
-
Lima, Peru, LIMA 34
- Research Site
-
Lima, Peru, LIMA 41
- Research Site
-
Lima, Peru, LIMA 31
- Research Site
-
Lima, Peru, Lima 32
- Research Site
-
San Isidro, Peru, 27
- Research Site
-
-
-
-
-
Kazan, Russian Federation, 420029
- Research Site
-
Kostroma, Russian Federation, 156005
- Research Site
-
Moscow, Russian Federation, 121205
- Research Site
-
Novisibirsk, Russian Federation, 630082
- Research Site
-
Obninsk, Russian Federation, 249036
- Research Site
-
Saint-Petersburg, Russian Federation, 197758
- Research Site
-
Saint-Petersburg, Russian Federation, 197022
- Research Site
-
Ufa, Russian Federation, 450054
- Research Site
-
-
-
-
-
Barcelona, Spain, 08003
- Research Site
-
Madrid, Spain, 28046
- Research Site
-
Madrid, Spain, 28040
- Research Site
-
Málaga, Spain, 29010
- Research Site
-
San Sebastián, Spain, 20014
- Research Site
-
Sevilla, Spain, 41009
- Research Site
-
Valencia, Spain, 46009
- Research Site
-
-
-
-
-
Kaohsiung, Taiwan, 83301
- Research Site
-
Taichung, Taiwan, 40705
- Research Site
-
Taichung, Taiwan, 40447
- Research Site
-
Taichung City, Taiwan, 402
- Research Site
-
Tainan City, Taiwan, 70403
- Research Site
-
Taipei, Taiwan, 10002
- Research Site
-
Taipei, Taiwan, 11217
- Research Site
-
Taoyuan, Taiwan, 00333
- Research Site
-
-
-
-
-
Bangkok, Thailand, 10300
- Research Site
-
Bangkok, Thailand, 10330
- Research Site
-
Bangkok, Thailand, 10400
- Research Site
-
Bangkok, Thailand, 10700
- Research Site
-
Hat Yai, Thailand, 90110
- Research Site
-
Khon Kaen, Thailand, 40002
- Research Site
-
Lampang, Thailand, 52000
- Research Site
-
Mueang, Thailand, 50200
- Research Site
-
-
-
-
-
Adana, Turkey, 01120
- Research Site
-
Adapazari, Turkey, 54290
- Research Site
-
Ankara, Turkey
- Research Site
-
Ankara, Turkey, 06280
- Research Site
-
Ankara, Turkey, 6200
- Research Site
-
Istanbul, Turkey, 34030
- Research Site
-
Istanbul, Turkey, 34854
- Research Site
-
Izmir, Turkey, 35620
- Research Site
-
-
-
-
California
-
Duarte, California, United States, 91010
- Research Site
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Research Site
-
-
New Jersey
-
Florham Park, New Jersey, United States, 07932
- Research Site
-
-
Utah
-
Salt Lake City, Utah, United States, 84106
- Research Site
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- Research Site
-
-
-
-
-
Hanoi, Vietnam, 100000
- Research Site
-
Hanoi City, Vietnam, 100000
- Research Site
-
Ho Chi Minh, Vietnam, 700000
- Research Site
-
Ho Chi Minh, Vietnam, 70000
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 130 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria
- Male or female aged at least 18 years.
- Patients with histologically documented NSCLC of predominantly non-squamous Pathology who present with locally advanced, unresectable (Stage III) disease (according to Version 8 of the International Association for the Study of Lung Cancer [IASLC] Staging Manual in Thoracic Oncology).
- The tumor harbours one of the two common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR mutations, assessed by cobas® EGFR Mutation Test v2 (Roche Diagnostics) or FoundationOne® test in a CLIA certified (USA sites) or an accredited local laboratory (sites outside of the USA) or by central testing (cobas® v2 only).
- Patients must have received either concurrent chemoradiation or sequential chemoradiation including at least 2 cycles of platinum based chemotherapy and a total dose of radiation of 60 Gy ±10% (54 to 66 Gy).
- Chemoradiation must be completed ≤6 weeks prior to randomization.
- Patients must not have had disease progression during or following definitive platinum-based, chemoradiation therapy.
- World Health Organization (WHO) performance status of 0 or 1.
- Life expectancy >12 weeks at Day 1.
- Female patients who are not abstinent (in line with the preferred and usual lifestyle choice) must be using adequate contraceptive measures, must not be breast feeding, and must have a negative pregnancy test prior to first dose of study drug; or female patients must have an evidence of non-childbearing potential.
Exclusion Criteria
- Mixed small cell and non-small cell lung cancer histology
- History of interstitial lung disease (ILD) prior to chemoradiation
- Symptomatic pneumonitis following chemoradiation
- Any unresolved toxicity Common Terminology Criteria for Adverse Events (CTCAE) > Grade 2 from the prior chemoradiation therapy
Any of the following cardiac criteria:
- Mean resting corrected QT interval (QTc) >470 msec, obtained from 3 ECGs
- Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG
- Patient with any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval and cause Torsades de Pointes
- Inadequate bone marrow reserve or organ function
- History of other malignancies, except: adequately treated non-melanoma skin cancer or lentigo maligna , curatively treated in-situ cancer, or other solid tumors curatively treated with no evidence of disease for > 5 years following the end of treatment and which, in the opinion of the treating physician, do not have a substantial risk of recurrence of the prior malignancy.
- Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses; or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV).
- Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of osimertinib
- Prior treatment with any prior chemotherapy, radiation therapy, immunotherapy or investigational agents for NSCLC outside of that received in the definitive setting for Stage III disease (chemotherapy and radiotherapy in SCRT and CCRT regimens is allowed for treatment of Stage III disease).
- Prior treatment with EGFR-TKI therapy
- Major surgery as defined by the investigator within 4 weeks of the first dose of study drug.
- Patients currently receiving (unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be strong inducers of CYP3A4 (at least 3 weeks prior to receiving the first dose of study drug).
- Contraindication to MRI, including but not limited to, claustrophobia, pace makers, metal implants, intracranial surgical clips and metal foreign bodies
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Osimertinib
Osimertinib (80mg or 40mg orally, once daily), in accordance with the randomization schedule.
|
The initial dose of Osimertinib 80mg once daily can be reduced to 40mg once daily.
Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met.
|
Placebo Comparator: Placebo Osimertinib
Matching placebo for Osimertinib (80mg or 40mg orally, once daily), in accordance with the randomization schedule
|
The initial dose of Placebo Osimertinib 80mg once daily can be reduced to 40mg once daily. Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival (PFS)
Time Frame: Approximately 13 months
|
Defined as the time from randomisation until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomised therapy or receives another anti-cancer therapy prior to progression, based on blinded independent central review assessment according to RECIST 1.1
|
Approximately 13 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PFS in patients with EGFR Ex19del or L858R mutation
Time Frame: Approximately 13 months
|
Defined as the time from randomisation until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomised therapy or receives another anti-cancer therapy prior to progression.' based on blinded independent central review assessment according to RECIST 1.1
|
Approximately 13 months
|
PFS in patients with EGFR mutations Ex19del or L858R detectable in plasma-derived ctDNA
Time Frame: Approximately 13 months
|
Defined as the time from randomisation until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomised therapy or receives another anti-cancer therapy prior to progression.' based on blinded independent central review assessment according to RECIST 1.1
|
Approximately 13 months
|
Time to CNS PFS
Time Frame: Approximately 13 months
|
Defined as earlier event of CNS progression or death based on blinded independent central review assessment according to RECIST 1.1
|
Approximately 13 months
|
Overall survival (OS)
Time Frame: Approximately 45 months
|
Defined as the time from randomization until death from any cause
|
Approximately 45 months
|
Objective response rate (ORR)
Time Frame: Approximately 13 months
|
Defined as the number (%) of patients with measurable disease with at least 1 visit response of CR (Complete response) or PR (Partial response) based on blinded independent central review assessment according to RECIST 1.1
|
Approximately 13 months
|
Duration of response (DoR)
Time Frame: Approximately 13 months
|
Defined as the time from the date of first documented response (i.e., subsequently confirmed) until the date of documented progression or death in the absence of disease progression based on blinded independent central review assessment according to RECIST 1.1
|
Approximately 13 months
|
Disease control rate (DCR)
Time Frame: Approximately 13 months
|
Defined as Disease control rate is defined as the percentage of subjects who have a best overall response of CR or PR or SD based on blinded independent central review assessment according to RECIST 1.1
|
Approximately 13 months
|
Tumor shrinkage
Time Frame: Approximately 13 months
|
Defined as the relative change in the sum of the longest diameters of RECIST target lesions at the nadir in the absence of new lesions or progression of non-target lesions compared to baseline based on blinded independent central review assessment according to RECIST 1.1
|
Approximately 13 months
|
Time to death or distant metastases (TTDM)
Time Frame: Approximately 13 months
|
Defined as the time from the date of randomization until the first date of distant metastasis or date of death in the absence of distant metastasis based on blinded independent central review assessment according to RECIST 1.1
|
Approximately 13 months
|
Time to treatment discontinuation
Time Frame: Approximately 13 months
|
Defined as the time from randomization to the earlier of the date of study treatment discontinuation (regardless of the reason for study treatment discontinuation) or death
|
Approximately 13 months
|
Second progression free survival on a subsequent treatment (PFS2)
Time Frame: Approximately 13 months
|
Time from randomisation to second progression (PFS2) is defined as the time from the date of randomisation to the earliest of the progression event subsequent to that used for the primary variable PFS or date of death after starting subsequent anti-cancer treatment.
|
Approximately 13 months
|
Time to first subsequent therapy (TFST)
Time Frame: Approximately 13 months
|
Defined as the time from the date of randomization to the earlier of the date of anti-cancer therapy start date following study drug discontinuation or death
|
Approximately 13 months
|
Time to second subsequent therapy (TSST)
Time Frame: Approximately 21 months
|
Defined as the time from the date of randomization to the earlier of the date of second subsequent anti-cancer therapy start date following study drug discontinuation or death.
|
Approximately 21 months
|
Patients reported disease-related symptoms and HRQoL by EORTC QLQ-LC13 and EORTC QLQ-30 questionnaires
Time Frame: Approximately 21 months
|
Change in symptoms from baseline
|
Approximately 21 months
|
Incidence of Adverse Events (AEs)
Time Frame: Approximately 13 months
|
AEs graded by CTCAE version 5.0
|
Approximately 13 months
|
Plasma concentrations of osimertinib and AZD5104
Time Frame: Trough concentrations at Week 4,12 and 24
|
The pharmacokinetics exposure parameters derived from plasma concentrations of osimertinib and AZD5104
|
Trough concentrations at Week 4,12 and 24
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Suresh S Ramalingam, MD, Emory University School of Medicine, Atlanta, U.S.
- Principal Investigator: Shun Lu, MD, Shanghai Chest Hospital, Shanghai, China
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 19, 2018
Primary Completion (Actual)
January 5, 2024
Study Completion (Estimated)
June 29, 2026
Study Registration Dates
First Submitted
April 20, 2018
First Submitted That Met QC Criteria
May 9, 2018
First Posted (Actual)
May 11, 2018
Study Record Updates
Last Update Posted (Actual)
April 26, 2024
Last Update Submitted That Met QC Criteria
April 25, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Tyrosine Kinase Inhibitors
- Osimertinib
Other Study ID Numbers
- D5160C00048
- 2018-001061-16 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.
All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD Sharing Time Frame
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles.
For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD Sharing Access Criteria
When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool .
Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access.
For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non Small Cell Lung Cancer (Stage III)
-
Oslo University HospitalAstraZenecaActive, not recruitingCancer | NSCLC | Non Small Cell Lung Cancer | NSCLC, Stage III | Non Small Cell Lung Cancer Stage IIINorway, Finland, Lithuania, Estonia
-
Stanford UniversityAstraZenecaRecruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage IIUnited States
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
Memorial Sloan Kettering Cancer CenterAstraZenecaRecruitingNSCLC | Lung Cancer | Non-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | PD-L1 Gene Mutation | Non-small Cell Lung Cancer Stage IIIA | Non-small Cell Lung Cancer Stage IIUnited States
-
Northwestern UniversityBristol-Myers Squibb; National Cancer Institute (NCI)UnknownStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage III Non-Small Cell Lung CancerUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IIIA Non-Small Cell Lung Cancer AJCC v7 | Stage III Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Cancer AJCC v7United States
-
Mayo ClinicNational Cancer Institute (NCI)TerminatedStage IV Non-Small Cell Lung Cancer AJCC v7 | Stage IIIA Non-Small Cell Lung Cancer AJCC v7 | Stage III Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Cancer AJCC v7 | Mesothelin PositiveUnited States
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI); NRG OncologyActive, not recruitingStage II Non-Small Cell Lung Cancer AJCC v7 | Stage IIA Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIB Non-Small Cell Lung Carcinoma AJCC v7 | Stage IIIA Non-Small Cell Lung Cancer AJCC v7 | Stage III Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Cancer AJCC v7United States
-
National Cancer Institute (NCI)NRG OncologyTerminatedStage IIIA Non-Small Cell Lung Cancer AJCC v7 | Stage III Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Cancer AJCC v7United States
Clinical Trials on Osimertinib 80mg/40mg
-
South China Center For Innovative PharmaceuticalsXiangya Hospital of Central South UniversityCompleted
-
CephalonCompleted
-
Samsung Medical CenterAstraZenecaCompletedEfficacy and Safety of 80mg Osimertinib in Patients With Non-small Cell Lung Cancer(NSCLC) (BLOSSOM)Non-small Cell Lung Cancer (NSCLC)Korea, Republic of
-
BeBetter Med IncCompleted
-
Linda Van EldikNational Institute on Aging (NIA); Duke Clinical Research InstituteCompleted
-
CephalonCompletedPsoriasisUnited States
-
Medicines for Malaria VentureUniversity of Cape TownCompleted
-
Nantes University HospitalAstraZenecaActive, not recruitingNon-small Cell Lung CancerFrance
-
Samsung Medical CenterRecruitingLung AdenocarcinomaKorea, Republic of
-
Sumitomo Pharma Co., Ltd.CompletedSchizophreniaChina, Japan, Korea, Republic of, Malaysia, Philippines, Russian Federation, Taiwan, Ukraine